Intravenous thrombolysis for acute ischemic stroke with extended time window

0
0
0

Intravenous thrombolysis for acute ischemic stroke with extended time window

Every year, millions of people worldwide face acute ischemic stroke (AIS), a devastating condition where a blood clot cuts off oxygen to the brain. The gold-standard treatment—intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA)—works best within 4.5 hours of symptom onset. But here’s a harsh reality: only 5% to 25% of AIS patients receive this life-saving therapy. Why? Many don’t know when their symptoms started (like “wake-up strokes,” where they find symptoms upon waking) or arrive at the hospital too late.

For years, doctors wondered if IVT could help patients with unclear onset times or who missed the 4.5-hour window. A 2021 meta-analysis by researchers at Sichuan University’s West China Hospital set out to find answers—and their results could change how we treat stroke. Led by Xue Jia, Wen Wang, Bo Wu, and Xin Sun from the Chinese Evidence-based Medicine Center and West China Hospital, the study analyzed data from four randomized controlled trials (RCTs) involving 848 patients, comparing IVT to placebo or usual care in AIS patients with extended time windows (>4.5 hours) or unclear symptom onset.

The team focused on four key outcomes: favorable functional recovery (modified Rankin Scale, or mRS, scores 0–1—meaning no symptoms or minor issues), functional independence (mRS 0–2—able to live independently with some limitations), symptomatic intracerebral hemorrhage (sICH) (bleeding in the brain that causes new symptoms), and death—all measured 90 days after treatment.

The results were striking:

  • More patients who got IVT achieved favorable recovery (45.8% vs. 36.7% in the placebo group) and functional independence (63.8% vs. 55.7%).
  • But IVT carried a higher risk of sICH (3.0% vs. 0.5% in the placebo group).
  • There was no significant difference in death rates (7.0% vs. 4.1%).

In short: IVT helped more patients regain independence or mild function, but it increased the chance of brain bleeding. The trade-off, however, was manageable—especially for specific groups: patients under 70, those with milder symptoms (National Institute of Health Stroke Scale, or NIHSS, ≤10), or who presented 9+ hours after onset. For these people, the benefits of IVT clearly outweighed the risks.

The study builds on earlier research showing that imaging—like MRI’s diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR)—can identify “viable” brain tissue even hours after symptom onset. For example, the 2018 WAKE-UP trial found that IVT helped patients with unknown onset times if their DWI showed a clot but FLAIR didn’t (a sign the stroke was recent). This meta-analysis confirms that IVT works beyond 4.5 hours when guided by imaging—and that it’s not just for patients who arrive “on time.”

Of course, the study has limitations. The sample size was small (four trials, 848 patients), and some trials didn’t specify which part of the brain was affected (e.g., anterior vs. posterior circulation). Also, while IVT improved outcomes, the risk of sICH means doctors must carefully weigh benefits against harms—especially for patients with severe symptoms (NIHSS >10), who had a higher bleeding risk.

But the takeaway is clear: IVT isn’t just for patients who arrive within 4.5 hours. For those with unclear onset times or who miss the window, MRI or CT perfusion imaging can help doctors decide if IVT is safe. As the researchers note, “Care of these patients should well balance the potential benefits and harms of IVT.”

This study adds to a growing body of evidence that stroke treatment isn’t one-size-fits-all. By using imaging to tailor care, doctors can extend the “window of opportunity” for IVT—and give more patients a chance to recover.

The meta-analysis was published in the Chinese Medical Journal in 2021. The original study authors are Xue Jia, Wen Wang, Bo Wu, and Xin Sun from Sichuan University’s Chinese Evidence-based Medicine Center, Department of Postgraduate, and Department of Neurology at West China Hospital.

doi.org/10.1097/CM9.0000000000001781

Was this helpful?

0 / 0